Liu A, Alalami H, Fan X, Patil C, Gill J, Kesari S
CNS Oncol. 2023; 12(3):CNS100.
PMID: 37435740
PMC: 10410685.
DOI: 10.2217/cns-2022-0021.
Grommes C, Pentsova E, Schaff L, Nolan C, Kaley T, Reiner A
Leuk Lymphoma. 2023; 64(9):1545-1553.
PMID: 37317993
PMC: 10529084.
DOI: 10.1080/10428194.2023.2223734.
Ma L, Gong Q
Transl Cancer Res. 2023; 12(5):1335-1352.
PMID: 37304530
PMC: 10248585.
DOI: 10.21037/tcr-22-2341.
Yerram P, Reiss S, Modelevsky L, Schaff L, Reiner A, Panageas K
Ann Lymphoma. 2023; 7.
PMID: 37067886
PMC: 10100595.
DOI: 10.21037/aol-22-19.
Wu S, Braunstein S, Rubenstein J, Sneed P
Cureus. 2023; 15(2):e34817.
PMID: 36915845
PMC: 10008121.
DOI: 10.7759/cureus.34817.
Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma.
Laucis A, Selwa K, Sun Y, Kim M, Cuneo K, Lawrence T
Neurooncol Pract. 2022; 9(6):536-544.
PMID: 36388411
PMC: 9665068.
DOI: 10.1093/nop/npac052.
Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.
Du S, Bota D, Kong X
Neurol Int. 2022; 14(3):574-580.
PMID: 35893281
PMC: 9326764.
DOI: 10.3390/neurolint14030046.
Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis.
Batara J, Apor A, Mojica C, Mondia M
Neurooncol Adv. 2022; 4(1):vdac105.
PMID: 35892049
PMC: 9307100.
DOI: 10.1093/noajnl/vdac105.
High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity.
Seidel S, Nilius-Eliliwi V, Kowalski T, Vangala D, Schlegel U, Schroers R
Cancers (Basel). 2022; 14(9).
PMID: 35565230
PMC: 9106040.
DOI: 10.3390/cancers14092100.
Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study.
Xiao J, Wang S, Xu B, Yu L, Han Y
J Healthc Eng. 2022; 2022:8963547.
PMID: 35392141
PMC: 8983235.
DOI: 10.1155/2022/8963547.
Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.
Ambady P, Doolittle N, Fox C
Ann Lymphoma. 2022; 5:23.
PMID: 35253010
PMC: 7612457.
DOI: 10.21037/aol-21-20.
Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome.
Singh C, Jain A, Takkar A, Agarwal A, Rohilla M, Lad D
Indian J Hematol Blood Transfus. 2022; 38(1):68-77.
PMID: 35125713
PMC: 8804055.
DOI: 10.1007/s12288-021-01438-5.
Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives.
Morales-Martinez A, Lozano-Sanchez F, Duran-Pena A, Hoang-Xuan K, Houillier C
Cancers (Basel). 2021; 13(14).
PMID: 34298693
PMC: 8303711.
DOI: 10.3390/cancers13143479.
Relapsed Primary Central Nervous System Lymphoma: Current Advances.
Tao K, Wang X, Tian X
Front Oncol. 2021; 11:649789.
PMID: 33996566
PMC: 8118624.
DOI: 10.3389/fonc.2021.649789.
Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies.
Holdhoff M, Wagner-Johnston N, Roschewski M
Onco Targets Ther. 2020; 13:8323-8335.
PMID: 32903865
PMC: 7445492.
DOI: 10.2147/OTT.S192379.
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
Dietrich J, Versmee L, Drappatz J, Eichler A, Nayak L, Norden A
Oncologist. 2020; 25(9):747-e1273.
PMID: 32520407
PMC: 7485351.
DOI: 10.1634/theoncologist.2020-0489.
Case-based review: primary central nervous system lymphoma.
Korfel A, Schlegel U, Johnson D, Kaufmann T, Giannini C, Hirose T
Neurooncol Pract. 2019; 4(1):46-59.
PMID: 31386044
PMC: 6656340.
DOI: 10.1093/nop/npw033.
miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.
Li X, Xu X, Chen K, Wu H, Wang Y, Yang S
Pathol Oncol Res. 2019; 26(2):707-714.
PMID: 30712191
PMC: 7242252.
DOI: 10.1007/s12253-019-00605-4.
Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.
Cai Q, Fang Y, Young K
Transl Oncol. 2019; 12(3):523-538.
PMID: 30616219
PMC: 6371000.
DOI: 10.1016/j.tranon.2018.11.011.
Introduction of novel agents in the treatment of primary CNS lymphoma.
Grommes C, Nayak L, Tun H, Batchelor T
Neuro Oncol. 2018; 21(3):306-313.
PMID: 30423172
PMC: 6380407.
DOI: 10.1093/neuonc/noy193.
